In a study published in the international journal hypertention, scientists from institutions such as the University of Hong Kong found that a drug commonly used to treat hypertension may help reduce the risk of colorectal cancer.
Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) drugs can be used to help treat a variety of diseases such as heart failure, hypertension or heart disease. These drugs can inhibit or block angiotensin, which is a molecule that can promote artery stenosis. Clinicians usually prescribe these drugs to patients with hypertension to help them relax Blood vessels, thereby lowering blood pressure.
Based on the results of a large-scale study, the researchers found that taking these drugs may also help reduce the risk of colorectal cancer, the third most common cancer in the world and the second leading cause of death in cancer patients worldwide Leung said that the role of ACE inhibitors and ARBs in the development of cancer is controversial. In some cases, the results are often contradictory. Previous studies have been limited by a variety of factors, including the small number of patients and short-term follow-up data. The results of this study highlight the potential role of these drugs in the prevention of colorectal cancer New ideas and opinions are provided.
In this study, the potential beneficial effects of ACE inhibitors and ARBs in the prevention of colorectal cancer were revealed for the first time, based on a large number of patients who did not have colorectal cancer at the beginning of the study. In this study, the health data of 187897 adult patients in Hong Kong from 2005 to 2013 were reviewed, and the baseline colonoscopy results of colorectal cancer were as follows: Negative, the researchers found: 1) individuals taking hypertension drugs such as ACE-I and ARBs had a 22% lower risk of colorectal cancer in the next three years; 2) the health benefits of ACE-I and ARBs drugs were observed in patients 55 years and older and in patients with a history of colorectal polyps; 3) drug related health benefits may be limited to negative baseline colonoscopy In the first three years, researcher Leung said that when drugs such as ACE-I and ARBs were taken by patients with hypertension, heart failure and kidney disease, the reduced risk of colorectal cancer may be another factor that clinicians should consider when choosing antihypertensive drugs.
Finally, the researchers said that this study was a retrospective study, and the researchers analyzed whether patients taking these drugs would develop colorectal cancer.
The results of this study should also be verified by prospective randomized controlled trials, and researchers should actively track patients to determine the potential benefits of these drugs in reducing the risk of colorectal cancer.